Login or Register
Biomedical Learning Institute Taught by the Experts
Thought Leaders
Biomedical Learning Institute
Please Note: The Oncology Learning Center has changed its name to Biomedical Learning Institute
Symposium Co-Chairs


George W. Sledge, Jr., MD
Ballve-Lantero Professor
of Oncology and Pathology
Co-Director, Breast Cancer Program
Indiana University Cancer Center
Co-Chair, Breast Committee,
The Eastern Oncology Cooperative Group
(ECOG)


Dennis J. Slamon, MD, PhD
Chief, Division of Hematology-Oncology
Professor and Executive Vice Chair, Department of Medicine
Director for Clinical Research
Jonsson Comprehensive Cancer Center
Director, Revlon/UCLA Women’s Health Research and Cancer Research Programs
University of California at Los Angeles School of Medicine
Los Angeles, CA

Expert Faculty


Carlos L. Arteaga, MD
Vice Chancellor's
Professor of Breast Cancer Research
Professor of Medicine and
Professor of Cancer Biology
Vanderbilt-Ingram Cancer Center
Nashville, TN


Edi Brogi, MD, PhD
Associate Professor of Clinical Pathology and Laboratory Medicine
Weill Medical College of Cornell University
Associate Attending Pathologist
Memorial Sloan-Kettering Cancer Center
New York, NY


Powel H. Brown, MD, PhD
Professor of Medicine,
Baylor College of Medicine
Associate Director of Cancer Prevention,
Dan L. Duncan Cancer Center
Director of Cancer Prevention and Population Sciences Program,
Dan L. Duncan Cancer Center
Associate Director of Research,
Breast Center
Baylor College of Medicine
Houston, TX


Lisa A. Carey, MD
Medical Director, UNC Breast Center
University of North Carolina
Lineberger Comprehensive Cancer Center
Chapel Hill, NC


David Flockhart, MD, PhD
Director, Division of Endocrinology and
Clinical Pharmacology
Indiana University School of Medicine
Indianapolis, IN


Clifford A. Hudis, MD
Chief, Breast Cancer Medicine Service
Memorial Sloan-Kettering Cancer Center
New York, NY
Co-Chair, Breast Committee,
The Cancer and Leukemia Group B
(CALGB)

Kelly K. Hunt, MD, FACS
Professor of Surgery
Chief, Surgical Breast Section
Department of Surgical Oncology
The University of Texas M. D. Anderson Cancer Center
Houston, TX


V. Craig Jordan, OBE, PhD, DSc
Senior Member Medical Science Division
Vice President and Scientific Director for Medical Science
Alfred G Knudson Jr. Chair in Cancer Research
Fox Chase Cancer Center
Philadelphia, PA


Allan Lipton, MD
Professor of Medicine and Oncology
M. S. Hershey Medical Center of
The Pennsylvania State University
Hershey, PA


Eleftherios P. Mamounas, MD, MPH, FACS
Professor of Surgery,
Northeastern Ohio Universities College of Medicine
Medical Director, Aultman Cancer Center
Canton, Ohio
Chairman, Breast Committee,
National Surgical Adjuvant Breast
and Bowel Project (NSABP)


Hyman Muss , MD
Professor of Medicine
Vermont Cancer Center of
Fletcher Allen Health Care
Burlington, VT


Mark Pegram, MD
Professor of Medicine and Oncology
University of Miami Cancer Center
Miami, FL


Edith A. Perez, MD
Professor of Medicine
Director, Clinical Research,
Mayo Clinic
Jacksonville, FL
Chair, Breast Committee,
The North Central Cancer Treatment Group
(NCCTG)


Charles M. Perou, PhD
Associate Professor
Department of Genetics
University of North Carolina
Chapel Hill, NC


Lori J. Pierce, MD
Vice Provost for Academic and Faculty Affairs Professor,
Department of Radiation Oncology
University of Michigan
Ann Arbor, MI


Malcom C. Pike, PhD

Professor and Acting Chair
Flora L. Thornton Professor
USC Norris Cancer Center
Los Angeles, CA


Michael F. Press, MD, PhD
Holder of Harold E. Lee Chair in Cancer Research
Professor of Pathology
Keck School of Medicine
USC Norris Cancer Center
Los Angeles, CA


Lajos Pusztai, MD, DPhil
Associate Professor of Medicine
Department of Breast Medical Oncology
The University of Texas
M. D. Anderson Cancer Center
Houston, TX


Daniel Silver, MD PhD
Instructor,
Department of Medicine
Harvard Medical School
Instructor, Cancer Biology
Dana-Farber Cancer Institute
Boston, MA


W. Fraser Symmans, MD
Professor of Pathology
The University of Texas
M. D. Anderson Cancer Center
Houston, TX

Katherine Weilbaecher, MD
Associate Professor of Medicine,
Washington University School of Medicine
Division of Molecular Oncology
St. Louis, MO


Jeffrey N. Weitzel, MD
Professor of Medicine,
Medical Oncology
Director of Clinical Cancer Genetics and Cancer Screening and Prevention Program
City of Hope Comprehensive Cancer Center,
Duarte, CA


Eric P. Winer, MD
Director, Breast Oncology Center
Thompson Investigator in Breast Cancer Research
Department of Medical Oncology
Dana-Farber Cancer Institute
Harvard Cancer Center
Boston, MA
Co-Chair, Breast Committee,
The Cancer and Leukemia
Group B (CALGB)

A 1 & 1/2 day, weekend, comprehensive course, taught by the distinguished experts in breast cancer, that is designed to help oncologists and hematologist/oncologists treat their breast cancer patients with a personalized approach, focusing on clinical therapies that can be applied today.

This symposium contains the most up-to-date clinical and scientific information on the personalized treatments of breast cancer.

Earn 13 AMA PRA Category 1 Credits while you are extensively interacting with the distinguished expert faculty through audience response selection of therapies for patient cases, voting on debates on critical topics, and involved in numerous panel discussions, consensus sessions, and asking questions of the faculty.


CO-CHAIRS

George W. Sledge, Jr., MD
Ballve-Lantero Professor of Oncology and Pathology
Co-Director, Breast Cancer Program
Indiana University Cancer Center, Indianapolis, IN
Co-Chair, Breast Committee, The Eastern Oncology Cooperative Group (ECOG)

Dennis J. Slamon, MD, PhD
Chief, Division of Hematology-Oncology
Professor and Executive Vice Chair, Department of Medicine
Director for Clinical Research
Jonsson Comprehensive Cancer Center
Director, Revlon/UCLA Women’s Health Research and Cancer Research Programs
University of California at Los Angeles School of Medicine
Los Angeles, CA



SESSION CHAIRS
and
ORGANIZING COMMITTEE

(and who also are faculty)

Lisa A. Carey, MD
Medical Director, UNC Breast Center
University of North Carolina
Lineberger Comprehensive Cancer Center
Chapel Hill, NC


Clifford A. Hudis, MD
Chief, Breast Cancer Medicine Service
Memorial Sloan-Kettering Cancer Center
New York, NY
Co-Chair, Breast Committee,
The Cancer and Leukemia Group B
(CALGB)


Allan Lipton, MD
Professor of Medicine and Oncology
M. S. Hershey Medical Center of
the Pennsylvania State University
Hershey, PA


Mark Pegram, MD
Professor of Medicine and Oncology
University of Miami Cancer Center
Miami, FL


Edith A. Perez, MD
Professor of Medicine
Director, Clinical Research,
Mayo Clinic
Jacksonville, FL
Chair, Breast Committee,
The North Central Cancer Treatment Group
(NCCTG)


Lori J. Pierce, MD
Vice Provost for Academic and Faculty Affairs Professor,
Department of Radiation Oncology
University of Michigan
AnnArbor, MI


Eric P. Winer, MD
Director, Breast Oncology Center
Thompson Investigator in Breast Cancer Research
Department of Medical Oncology
Dana-Farber Cancer Institute /
Harvard Cancer Center
Boston, MA
Co-Chair, Breast Committee,
The Cancer and Leukemia Group B
(CALGB)

   
Why Attend This Symposium
What's New This Year
Educational Statement of Need
Overview
Disclosure
Target Audience
Learning Objectives
CME Credit Information
Agenda
Faculty
Educational Grants
InterContinental Hotel Information
Registration
   

Agenda Back to Top
January 23, 2009 - Friday
5:00PM - 9:00PM Early On-Site Registration Participants
January 24, 2009 - Saturday
7:00AM - 8:00AM Buffet Breakfast Participants and Faculty
7:00AM - 8:00AM On-Site Registration (continued) Participants
8:00AM - 8:10AM Welcome and Pre-Activity CME Test Using the Audience Response System Participants and Symposium
Co-Chairs:
Drs. Slamon and Sledge
Session 1 Personalizing Therapies for the Prevention of Breast Cancer Chair: Dr. Pegram
8:10AM - 8:30AM Predicting who will develop breast cancer Dr. Pike
8:30AM - 8:50AM The clinical application of genetic testing for breast cancer prevention Dr. Weitzel
8:50AM - 9:10AM Drug prevention strategies using SERMS and other agents for patients at high risk of developing breast cancer Dr. Brown
9:10AM - 9:30AM Point-CounterPoint #1
All patients at high risk for developing breast cancer should receive SERMS prophylactically
1. Audience votes
2. Pro: Dr. Brown
3. Con: Dr. Weitzel
4. Audience votes
9:30AM - 9:45AM Session 1 Case Study Dr. Pegram presents and Participants select treatment strategy
9:45AM -10:00AM Panel Discussion, Q&A and Consensus on the Status of the Data Presented in this Session:
1. Is it a new standard of care?
2. Should it be discussed with your patients?
3. How can you use it today?
Session 1 Faculty and Participants
1. Each faculty addresses all three questions
2. Audience Votes on questions 1 and 2
10:00AM -10:15AM BREAK  
Session 2 Diagnosis and Molecular Classifications of Breast Cancer for Personalizing Therapies Chair: Dr. Burstein
10:15AM -10:30AM In which patients with breast cancer are gene expression arrays beneficial as prognostic markers today? Dr. Perou
10:30AM -10:50AM Clinical applications of gene expression profiling-based prediction of complete pathologic response to neo-adjuvant taxane/FAC chemotherapy in breast cancer? Dr. Pusztai
10:50AM -11:10AM Point-CounterPoint #2 Use the 70-gene microarray assay [IVDMIA (in-vitro diagnostic multivariate index assay) ] diagnostic versus the 21-gene panel assay for testing ER+, node-negative breast cancer 1. Audience votes
2. for the 70-gene microarray assay: Dr. Pusztai
3. for the 21-gene panel assay: Dr. Sledge
4. Audience votes
11:10AM -11:30AM Session 2 Case Study Dr. Burstein presents and Participants select treatment strategy
11:30AM -11:45AM Panel Discussion, Q&A and Consensus on the Status of the Data Presented in this Session:
1. Is it a new standard of care?
2. Should it be discussed with your patients?
3. How can you use it today?
Session 2 Faculty and Participants
1. Each faculty addresses all three questions
2. Audience Votes on questions 1 and 2
11:45AM - 12:45PM LUNCH with the Professors:
Each of today’s faculty will be assigned a separate lunch table so that the symposium participants can further interact with a faculty member on his/her presentation or topic
Participants and Faculty
Session 3 Personalized Approaches to Early Therapy of Breast Cancer Chair: Dr. Pierce
12:45PM - 1:05PM Individualizing local-regional control with neo-adjuvant chemotherapy Dr. Mamounas
1:05PM - 1:25PM Personalizing radiation therapy Dr. Pierce
1:25PM - 1:45PM Personalizing surgical therapy Dr. Hunt
1:45PM - 2:05PM Point-CounterPoint #3
T[a taxane]+C[a platinum]+H[an anti-HER2] should replace anthracycline-based therapies for adjuvant therapy of HER2-positive breast cancer
1. Audience votes
2. Pro: Dr. Slamon
3. Con: Dr. Burstein
4. Audience votes
2:05PM - 2:20PM Session 3 Case Study Dr. Pierce presents and Participants select treatment strategy
2:20PM - 2:35PM Panel Discussion, Q&A and Consensus on the Status of the Data Presented in this Session:
1. Is it a new standard of care?
2. Should it be discussed with your patients?
3. How can you use it today?
Session 3 Faculty and Participants
1. Each faculty addresses all three questions
2. Audience Votes on questions 1 and 2
2:35PM - 2:50PM BREAK  
Session 4 Clinical Applications of Personalized Therapies for HER2+ Breast Cancers Chair: Dr. Slamon
2:50PM - 3:10PM Personalized approaches to selecting targeted therapies and chemotherapies for metastatic HER2+ breast cancer patients Dr. Slamon
3:10PM - 3:30PM Predictors of response and personalized approaches to selecting patients for adjuvant and neo-adjuvant anti-HER2 therapy for HER2 breast cancer Dr. Arteaga
3:30PM - 3:50PM The relationship between HER2 expression and response to taxane-based therapies Dr. Muss
3:50PM - 4:10PM Point-CounterPoint #4
Adjuvant anti-HER2 strategies should be considered for HER2-negative patients?
1. Audience votes
2. Pro: Dr. Muss
3. Con: Dr. Press
4. Audience votes
4:10PM - 4:30PM Point-CounterPoint #5
A taxane plus an alkylating agent should replace anthracycline-based therapies for adjuvant therapy of HER2-negative breast cancer
1. Audience votes
2. Pro: Dr. Muss
3. Con: Dr. Burstein
4. Audience votes
4:30PM - 4:45PM Session 4 Case Study Dr. Slamon presents and Participants select treatment strategy
4:45PM - 5:00PM Panel Discussion, Q&A and Consensus on the Status of the Data Presented in this Session:
1. Is it a new standard of care?
2. Should it be discussed with your patients?
3. How can you use it today?
Session 4 Faculty and Participants
1. Each faculty addresses all three questions
2. Audience Votes on questions 1 and 2
5:00PM DINNER "On Your Own"
 
January 25, 2009 - Sunday
Session 5 Clinical Applications of Personalized Therapies for ER+ Breast Cancers Chair: Dr. Perez
7:00AM - 8:00AM Buffet Breakfast Participants and Faculty
8:00AM - 8:20AM What are the molecular predictors of response to adjuvant endocrine therapy? Dr. Symmans
8:20AM - 8:40AM Are there personalized strategies for overcoming resistance to endocrine therapy? Dr. Jordan
8:40AM - 8:50AM Personalized approaches to treating patients with ER+ breast cancer using single nucleotide polymorphisms (SNPs) Dr. Flockhart
8:50AM - 9:10AM Point-CounterPoint #6
Systemic therapy for the elderly should be identical to that for younger patients
1. Audience votes
2. Pro: Dr. Perez
3. Con: Dr. Sledge
4. Audience votes
9:10AM - 9:30AM Session 5 Case Study Dr. Perez presents and Participants select treatment strategy
9:30AM - 9:50AM Panel Discussion, Q&A and Consensus on the Status of the Data Presented in this Session:
1. Is it a new standard of care?
2. Should it be discussed with your patients?
3. How can you use it today?
Session 5 Faculty and Participants
1. Each faculty addresses all three questions
2. Audience Votes on questions 1 and 2
9:50AM - 10:10AM BREAK  
Session 6 Clinical Applications of Personalized Therapies for Triple-Negative Disease Co-Chairs: Drs. Carey and Hudis
10:10AM - 10:30AM Pathology and molecular classification of Triple-Negative Disease Dr. Brogi
10:30AM - 10:50AM Personalizing brest cancer therapies using anti-angiogenic strategies Dr. Sledge
10:50AM - 11:10AM Therapeutic Individualization with specific chemotherapeutic agents Dr. Carey
11:10AM - 11:30AM Point-CounterPoint #7
All triple-negative patients should receive platinum-based adjuvant therapy
1. Audience votes
2. Pro: Dr. Carey
3. Con: Dr. Hudis
4. Audience votes
11:30AM - 11:45AM Session 6 Case Study Drs. Carey and Hudis present and Participants select treatment strategy
11:45AM - 12:00PM Panel Discussion, Q&A and Consensus on the Status of the Data Presented in this Session:
1. Is it a new standard of care?
2. Should it be discussed with your patients?
3. How can you use it today?
Session 6 Faculty and Participants
1. Each faculty addresses all three questions
2. Audience Votes on questions 1 and 2
12:00PM - 1:00PM LUNCH with the Professors:
Each of today’s faculty will be assigned a separate lunch table so that the symposium participants can further interact with a faculty member on his/her presentation or topic
Participants and Faculty
Session 7 New Developments in the Treatment of Bone Metastases, and the Management of Bone Health and Bone Integrity Chair: Dr. Lipton
1:00PM -1:20PM Drugs treating bone metastases: Are they supportive care agents, therapeutics or both? Dr. Weilbaecher
1:20PM -1:40PM Newer clinical strategies for treating bone metastases, including inhibition of RANK Ligand Dr. Lipton
1:40PM - 2:00PM Point-CounterPoint #8 Drugs treating bone metastases should be offered to patients as an option for adjuvant therapy of breast cancer 1. Audience votes
2. Pro: Dr. Weilbaecher
3. Con: Dr. Lipton
4. Audience votes
2:00PM - 2:20PM Session 7 Case Study Dr. Lipton presents and Participants select treatment strategy
2:20PM - 2:40PM Panel Discussion, Q&A and Consensus on the Status of the Data Presented in this Session:
1. Is it a new standard of care?
2. Should it be discussed with your patients?
3. How can you use it today?
Session 7 Faculty and Participants
1. Each faculty addresses all three questions
2. Audience Votes on questions 1 and 2
2:40PM - 2:50PM Post-Activity CME Test Using the Audience Response System Participants and Symposium Co-Chairs: Drs. Slamon and Sledge
Educational Grants

Sincere appreciation is extended to the following companies for their generous commercial support of this educational meeting (Genentech BioOncology, Bristol-Myers Squibb, Novartis, sanofi aventis, Genomic Health, Clarient, Inc., and Agendia):

 

Genentech BioOncology
BMS
Novartis
sanofi aventis
Genomic Health
Clarient, Inc.
Biogen Idec
Agendia
© 2012 Biomedical Learning Institute
1415 Legacy Drive, Suite 250 • Frisco, TX 75034 • Registration Phone: 214.269.2014 • Fax: 214.866.0311
Contact Us
Disclaimer: The material published on the Biomedical Learning Institute(BLI) Web site reflects the opinions and expertise of the authors and/or reviewers of the material, and not the opinions of the BLI, the CME provider, or the commercial supporters providing educational grants. The materials may address uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. Before using any therapeutic approaches reviewed in this material, a qualified physician should be consulted. Readers of this content should verify all information and data before treating patients or using any drugs or therapies described in any BLI materials. Click here for our Privacy Policy.